Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Daily News

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

L.A. McKeown

June 18, 2024

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

L.A. McKeown

October 12, 2016

News Daily News

PAD Patients Do Better When Endovascular Therapy Added to Exercise Program

Caitlin E. Cox

November 15, 2015

News Daily News

OLIVE Registry: Endovascular Therapy Outcomes for CLI ‘Reasonable’ at 3 Years

L.A. McKeown

September 23, 2015

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

PAD Patients Do Better When Endovascular Therapy Added to Exercise Program

OLIVE Registry: Endovascular Therapy Outcomes for CLI ‘Reasonable’ at 3 Years

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content